Phase 3 randomized study of datopotamab deruxtecan (DS-1062A) versus docetaxel in previously treated advanced non-small cell lung cancer without actionable genomic alterations (TROPION-LUNG01)

UVA Tracking #
Principal Investigator
Richard Hall
Contact Phone
Official Trial Title
Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have non-small cell lung cancer without mutations. The purpose of this study to evaluate an investigational drug (DS-1062A) compared to a chemotherapy drug (docetaxel) in patients with non-small cell lung cancer. The safety and effects of the investigational drug will be evaluated for this study.

Participation includes a screening period, 3 week cycles of treatment, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study treatment as long as the treatment is still helping your disease. Study specific test will be provided at no cost to you.

Additional information can be found here:


o Reimbursement: You will receive up to $175 for hotel stays per night.


You will receive $50 per study visit.